Replies to post #111757 on PharmaCyte Biotech Inc (PMCB)

[rcstock]

Just a maintenance type drug.

[DragonBear]

Might be approved but it sucks

Yeah, a drug with a low side effect profile, giving 22% responding patients 2 yrs to live instead of months would really suck for PC victims.

No doubt, the excitement over the ASCO presentation last Jul was because ... it sucks. LOL